Research map: Impact of Flow Cytometry-Based MRD Detection in Predicting Outcome in Indian AML Patients: Real-World Data of 125 patients

Back to the article

Papers in this map

  1. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN · Hartmut Döhner · 2022 · 3298 citations · Cited by this paper
  2. Dual Driver Myeloproliferative Neoplasms: CALR-Mutated Essential Thrombocythemia Coexisting With Chronic Myeloid Leukemia · 2026 · Related
  3. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia · Nicholas James Short · 2020 · 394 citations · Cited by this paper
  4. Role of Reticulocyte Parameters as Adjunct in Antenatal Screening for β-Thalassemia Trait · 2026 · Related
  5. Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia · Sylvie D. Freeman · 2013 · 317 citations · Cited by this paper
  6. Prevalence and Clinical Profile of Thyroid Dysfunction in Transfusion-Dependent Thalassemia: A Prospective Observational Study in a Tertiary Care Center · 2026 · Related
  7. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial · Wolfgang Kern · 2002 · 285 citations · Cited by this paper
  8. Waldenström Macroglobulinemia: Current Concepts in Diagnosis and Management · 2026 · Related
  9. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations · Hartmut Döhner · 2024 · 242 citations · Cited by this paper
  10. Hemorrhagic Stroke in Pediatric Sickle Cell Disease: A Case Series · 2026 · Related
  11. Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia · Keith William Pratz · 2024 · 226 citations · Cited by this paper
  12. The Hidden Burden of Undiagnosed Psychological Stress Among Patients with Iron Deficiency Anemia · 2026 · Related
  13. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia · Christian R. Rausch · 2023 · 108 citations · Cited by this paper
  14. Pediatric Myelofibrosis: State of the Art · 2026 · Related
  15. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party · Jesse M. Tettero · 2021 · 92 citations · Cited by this paper
  16. Network Analysis of Antibiotic Co-Resistance in Gram-Negative Sepsis in Acute Leukaemia · 2026 · Related
  17. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia · Marisa J.L. Aitken · 2021 · 83 citations · Cited by this paper
  18. Acute Bone Marrow Infarction and Reactive Myositis in Transfusion-Dependent Beta-Thalassaemia · 2026 · Related
  19. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party · Jacqueline J Cloos · 2025 · 63 citations · Cited by this paper
  20. Lineage Switch in Acute Leukaemia: A Four-Case Series Highlighting Clonal Evolution and Post-Transplant Plasticity · 2026 · Related
  21. Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy · Fieke W. Hoff · 2024 · 36 citations · Cited by this paper
  22. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) · Ing Soo Tiong · 2024 · 30 citations · Cited by this paper
  23. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia · Maximilian Alexander Röhnert · 2022 · 28 citations · Cited by this paper
  24. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients · Shai O. Shimony · 2024 · 27 citations · Cited by this paper
  25. Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel · Christian Michel Zwaan · 2025 · 25 citations · Cited by this paper
  26. Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context · Nikhil V. Patkar · 2019 · 21 citations · Cited by this paper
  27. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study · Teresa Caballero‐Velázquez · 2023 · 20 citations · Cited by this paper
  28. MRD in AML: who, what, when, where, and how? · Kieran D. Sahasrabudhe · 2024 · 14 citations · Cited by this paper
  29. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials · Nicola E. Potter · 2025 · 14 citations · Cited by this paper
  30. Novel classification system and high-risk categories of pediatric acute myeloid leukemia · Masayuki Umeda · 2025 · 13 citations · Cited by this paper
  31. Flow cytometric measurable residual disease in adult acute myeloid leukemia: a preliminary report from Eastern India · Neha Singh · 2023 · 2 citations · Cited by this paper
  32. Optimal Time Point for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia Patients · Meatanun Charoonkolaks · 2024 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)